zxclear

zxclear

[KR-바이오] 07/30 Korea Market Insights

삼성바이오로직스호재 As a senior equity analyst, I evaluate Samsung Biologics’ acquisition of (Polypeptide Group) for approximately KRW 2.7 trillion as a highly strategic and transformative move. This landmark (M&A)—the largest in the history of the Korean biotech industry—enables the company…